New cancer drug trial halted after early testing phase
NCT ID NCT06391775
Summary
This early-stage trial tested a new cancer drug called GEN1055, both alone and combined with an existing immunotherapy drug (pembrolizumab), for people with advanced solid tumors. The study aimed to find safe doses and see if the treatment could shrink tumors. The trial was terminated after enrolling 21 participants, and results from this limited testing are not yet publicly available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Hospital Universtari Val D´Hebron
Barcelona, Spain
-
Start Madrid Ciocc Hm Sanchinarro
Madrid, Spain
-
Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.